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Introduction
Traumatic brain injury (TBI) is one of the primary causes of death and disability.1 TBI
occurs from sudden head injury that damages the brain and interrupts its normal functioning. The
severity of a TBI ranges from “mild” (i.e., loss of consciousness shorter than 30 minutes) to
“severe” (i.e., extended period of unconsciousness usually greater than 6 hours).1 According to
the US Centers for Disease Control and Prevention (CDC) in 2014, over 2 million TBI-related
emergency department visits and hospitalizations occurred with over 56,000 of them leading to
death.1 Mortality rates after brain injury are highest in those with severe TBI. The vast number of
hospitalizations and deaths from TBI is attributed to complications such as posttraumatic
seizures, deep vein thrombosis, chronic traumatic encephalopathy (CTE), and intracranial
hypertension (ICH).1 ICH is often present in the acute setting and is associated with poor
neurologic outcomes and death. Hence, treating this disorder is critical.
Elevated intracranial pressure (ICP), which is caused by cerebral edema, is a serious
potential complication of TBI resulting in ICH. Thus, effective and reliable guidelines for the
management of patients with elevated ICP should be identified. In order to prevent potential
damages due to ICH, prompt recognition, urgent assessment, and expeditious therapy directed at
reducing ICP are required. In adults, normal ICP is < 15 mmHg and pathologic ICH is present at
pressures > 20 mmHg, with normally lower ICP values in children.2 The intracranial contents
consist of 80% brain parenchyma, 10% cerebrospinal fluid, and 10% blood.2 With normal
intracranial compliance, ICP is autoregulated to maintain normal pressures. This autoregulatory
ability malfunctions in pathologic states such as TBI resulting in cerebral edema and increases in
ICP.2
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When ICP rises, signs and symptoms can include pupillary asymmetry, fixed and dilated
pupils, decorticate or decerebrate posturing, peripheral hypertension, bradycardia, respiratory
irregularity, headache, decrease in consciousness, and vomiting.2 Patients who exhibit these
signs and symptoms require urgent ICP monitoring and prompt initiation of treatment. Current
recommendations for care of acute severe TBI, based on recent guidelines, include admission to
the intensive care unit along with airway management and ventilation (to avoid hypoventilation),
monitoring of vital signs (especially temperature, pulse oximetry, respiratory rate, and blood
pressure; watching for fever, hypoventilation, and hypotension), antifibrinolytic therapy (if
indicated), glucose monitoring (to avoid hyperglycemia), antiepileptic drugs (to prevent
seizures), electroencephalography (EEG), and maintenance of euvolemia via IV fluids.3
Since elevated ICP is complicated by higher mortality and serious neurologic deficits, its
prevention and treatment are key. Osmotic agents can decrease cerebral edema and thus, ICP.
This therapy is used in TBI patients who have clinical manifestations of cerebral edema and ICH
or have a documented elevated ICP.3 Specifically, two osmotic agents, hypertonic saline (HTS)
and mannitol (MNT), have been shown to be effective for ICP.3 Nonetheless, whether one agent
is superior to the other has yet to be determined. Each osmotic agent has theoretical advantages.
HTS has several theoretical advantages over MNT including intravascular volume replenishment
and prevention of hypovolemia.3 Moreover, HTS appears to improve tissue oxygenation of the
brain more than MNT since HTS has less chance of leaking into brain parenchyma and
interfering with the functional tissue of the brain.3 A theoretical advantage of MNT is its effects
on brain circulation. Although the mechanism of action of MNT isn’t fully understood, it is
thought to lower ICP by reducing blood viscosity. This in turn helps cerebral blood flow and
ultimately reducing cerebral blood volume and ICP.3 Additionally, MNT reduces ICP by
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withdrawing water from the brain parenchyma and is excreted in urine. 3 Examining the currently
available evidence may establish which osmotic agent is more effective.

Discussion
Administration of hyperosmolar agents, such as mannitol (MNT) and hypertonic saline
(HTS), creates an osmotic gradient within the blood brain barrier and allows cerebrospinal fluid
to flow out of the cranium leading to a decrease in ICP.3 MNT was historically the treatment of
choice but HTS is becoming the preferred treatment for elevated ICP.4 Many studies have shown
that both osmolar therapies are effective for decreasing ICP; however, choosing one over the
other as the gold standard therapy is difficult because of conflicting findings in the available
research.
In a systematic review article by Boone et al., seven studies including five prospective,
randomized trials; one nonrandomized, prospective trial; and one retrospective cohort study all
found that both osmolar therapies were effective in reducing ICP but the heterogeneity among
these studies precluded determination of which agent was more efficacious.4 Most of these
studies showed that both HTS and MNT were equally effective, while some of the studies found
that HTS was superior to MNT because it decreased ICP more quickly or to a greater extent or
both.4 Many of these published studies had major limitations because they only focused on ICP
management without considering additional factors such as cerebral perfusion pressure and
clinical outcomes.
Similarly, findings from another study by Francony et al. were comparable to previous
reports. In a parallel, randomized, control trial, a total of 20 patients with ICP > 20 mmHg
received an equimolar dose of 20% MNT or 7.45% HTS. The times required to effect ICP
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changes were similar in the two groups. At 60 minutes MNT reduced ICP by 45% + 19% (mean
+ standard deviation) and HTS reduced ICP 35% + 14% compared with baseline values at 0
minutes.5 This study demonstrated that 20% MNT was equally effective as 7.45% HTS for
reducing ICP in patients with brain injury.5 There were no significant differences in effectiveness
of ICP with MNT or HTS to preclude one method over the other. Additionally, the study
highlighted other possible effects of hyperosmolar therapy. For instance, MNT had beneficial
effects on brain circulation through possible improvement in blood viscosity whereas HTS
caused elevations of serum sodium and chloride, both adverse effects.5 The researchers
suggested that MNT could be the first line treatment in patients with cerebral hypoperfusion and
that hypertonic saline could be reserved for patients with hypovolemia or hyponatremia.5 When
considering the available choices for osmolar treatment of ICP, these additional unintended
effects from therapy should be weighed. These disparate unintended effects could explain the
difficulty in determining which therapy is superior.
Other studies, with findings contrary to the above studies, found evidence for superiority
of one agent compared with another. In a prospective, randomized, controlled pilot study by
Battison et al. evaluating nine patients with ICH both MNT (median decrease, 7.5 mmHg, 95%
confidence interval, 5.8-11.8) and HTS (median decrease, 13 mmHg; 95% confidence interval,
11.5-17.3) reduced ICH, but HTS provided a significantly greater reduction in ICP (p = .044)
and had a longer duration of effect (p = .044) than MNT. Both were given in equimolar
concentrations and by rapid, intravenous infusion.6 Limitations of this study included lack of
generalizability and low quality evidence because of its small sample size. In a prospective
observational study by Shein et al., 16 children < 18 years old with severe TBI, GCS score < 8
who had ICP monitoring were treated with HTS, fentanyl, or phenobarbital. HTS administration
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was associated with the most rapid resolution of ICH compared to the other inventions.7
Although the sample size was small, the data consisting of > 2,700,000 individual time points
provided a strength. The small sample size and the observational design of this study limited its
ability to suggest causality. Moreover, long-term outcomes were not followed. In addition, the
exclusion criteria eliminated participants who received MNT so a comparison with HTS was not
available.7 In a 2008 prospective randomized study by Vialet et al., participants with refractory
post-traumatic ICH were treated with increasing osmotic loads of HTS. In this study, increasing
osmotic load by giving 2mL/kg of 7.5% saline was more effective than giving 2mL/kg of 20%
MNT and the failure rate of HTS was comparatively lower than that in MNT.8 The researchers
suggested that HTS is an effective and safe initial treatment for ICH since there were fewer
episodes of ICH and shorter durations of ICH in the HTS group than in the MNT group.8 No
clinically significant perturbations in serum sodium (osmolality) were found. Although ICP was
measured, clinical outcomes were not assessed. 8 In a randomized control trial using MNT in
comparison with other ICP lowering agents such as HTS, MNT increased the likelihood of
death.9 Given this finding, it is imperative to find more effective and reliable alternatives,
possibly HTS, for reducing ICP. Although the sample size in this trial was too small for deducing
a reliable conclusion, the possible risk of death after infusion of MNT is too serious to dismiss
when selecting an ICP lowering agent. In a retrospective study looking at data from ten earlier
studies, this study assessed the impact of HTS administration on TBI outcomes and hypothesized
that favorable outcomes would be associated with larger amounts of 3% saline.10 Beneficial
outcomes were associated with the administration of larger amounts of HTS in specific groups of
patients with complex TBI, including higher trauma center survival, greater ICH containment,
and better ability to follow commands at three months when given larger quantities of HTS.10
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Principal limitations were the retrospective study design and patient information gathered from
only one institution. A prospective study is needed to provide an independent set of observations
to see if similar results are found. Since research on side effects of HTS is still limited,
considering other clinical factors is still required to determine which osmolar agent is best for
each patient.
Summary
Most of these studies found that HTS was superior to MNT for osmotic treatment of ICH
due to TBI. Potential adverse effects were less with HTS. The studies were limited because of
the small sample sizes, the short-term follow-up, and the focus on ICH changes rather than longterm clinical outcomes, such as death and neurologic sequelae. Although risks are inherent with
either treatment, weighing the risks versus benefits across both treatment options points to better
ICP management with HTS. These studies were limited because they examined surrogate
outcomes such as ICP rather than clinical outcomes such as mortality, disease progression,
patient’s symptoms and overall effect on function or quality of life. Moreover, the small sample
sizes of these studies limited their power and generalizability. Although the studies provided
evidence that HTS may be superior to MNT, both of their risks of adverse effects attenuate this
evidence. Further research is necessary before HTS can be definitively recommended over MNT.
No specific hyperosmolar treatment protocol has been shown to improve function outcome or
mortality in clinical trials. Different types of HTS solutions and different methods of
administration, continuous versus bolus dose, need to be evaluated to effectively recommend one
osmotic agent over the other. Specific trials are needed to determine whether certain types of
patients respond better to HTS than MNT, and vice versa. Although MNT proves to be
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comparable to HTS in some studies, it comes with a greater risk of mortality that most providers
may not be willing to take.

Conclusion
The question of whether to use MNT or HTS therapy for ICH due to TBI has not been
fully answered. MNT was the preferred treatment decades ago, but HTS is beginning to establish
itself as the initial option for treatment of elevated ICP based on these data. Most of the available
studies support the contention that ICH due to TBI can be reduced with osmotic therapy and that
HTS, instead of MNT, may be recommended as the treatment of choice (or the first-line
treatment). Future investigations should determine the definitive osmolar therapy for treatment of
ICH from TBI, or at least set parameters for which agent would better in different clinical
situations. Additional research is warranted with larger sample sizes and randomized controlled
trials since uncertainty remains over the optimal therapy. At this point, lacking reliable evidence
precludes definite recommendations for the use of HTS over MNT. Nonetheless, as evidenced in
recent studies, HTS may be preferred in patients who are hypovolemic or hyponatremic.
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